The U.S. FDA has approved Ferring Pharmaceuticals’ drug product manufacturing hub in Parsippany, New Jersey, for its intravesical non-replicating gene therapy, Adstiladrin.
🧪🧬⑂ #GeneTherapy #SciComm
🧪🧬⑂ #GeneTherapy #SciComm
Ferring expands gene therapy production to U.S. site
The U.S. FDA has approved Ferring’s drug product manufacturing hub in Parsippany, New Jersey, for its intravesical non-replicating gene therapy, Adstiladrin.
www.cellgenetherapyreview.com
April 28, 2025 at 3:59 PM
The U.S. FDA has approved Ferring Pharmaceuticals’ drug product manufacturing hub in Parsippany, New Jersey, for its intravesical non-replicating gene therapy, Adstiladrin.
🧪🧬⑂ #GeneTherapy #SciComm
🧪🧬⑂ #GeneTherapy #SciComm
Does your Dr. make
you flip side to side
during treatment? A very unscientific poll #bladdercancer #bcgtreatment #gemcitabine #chemotherapy #adstiladrin
you flip side to side
during treatment? A very unscientific poll #bladdercancer #bcgtreatment #gemcitabine #chemotherapy #adstiladrin
December 17, 2025 at 2:23 AM
Does your Dr. make
you flip side to side
during treatment? A very unscientific poll #bladdercancer #bcgtreatment #gemcitabine #chemotherapy #adstiladrin
you flip side to side
during treatment? A very unscientific poll #bladdercancer #bcgtreatment #gemcitabine #chemotherapy #adstiladrin
Wow. Stay strong. I've been treating bladder cancer for 2 years. My urologist stated I was a "refractory patient" because BCG didn't work & now Keytruda is not working. I'm afraid a cystectomy is near. One more encouraging new drug called Adstiladrin, but it's $60,000 a dose.
December 29, 2024 at 10:43 PM
Wow. Stay strong. I've been treating bladder cancer for 2 years. My urologist stated I was a "refractory patient" because BCG didn't work & now Keytruda is not working. I'm afraid a cystectomy is near. One more encouraging new drug called Adstiladrin, but it's $60,000 a dose.
FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC
https://cancerletter.com/drugs-and-targets/20260327_11c/
https://cancerletter.com/drugs-and-targets/20260327_11c/
FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC - The Cancer Letter
FDA approved a label update that will accelerate thaw time for Adstiladrin (nadofaragene firadenovec-vncg), gene therapy for adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams. To access this subscriber-only content please log in or subscribe.If your […]
cancerletter.com
March 31, 2026 at 3:00 PM
FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC
https://cancerletter.com/drugs-and-targets/20260327_11c/
https://cancerletter.com/drugs-and-targets/20260327_11c/
CHMP cites single-arm pivotal evidence with complete response and durability signal while post-authorisation data remain pending https://www.mattheneus.com/editorial/ema-adstiladrin-conditional-opinion-bcg-unresponsive-nmibc-single-arm-lineage-2026-03-26 #HTA #EvidenceSynthesis
March 29, 2026 at 8:36 PM
CHMP cites single-arm pivotal evidence with complete response and durability signal while post-authorisation data remain pending https://www.mattheneus.com/editorial/ema-adstiladrin-conditional-opinion-bcg-unresponsive-nmibc-single-arm-lineage-2026-03-26 #HTA #EvidenceSynthesis
Link: http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin
Date: 2025-10-10
Date: 2025-10-10
October 12, 2025 at 5:00 AM
Link: http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/adstiladrin
Date: 2025-10-10
Date: 2025-10-10
ADSTILADRIN
October 12, 2025 at 5:00 AM
ADSTILADRIN
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Monday, November 3, 2025
Published on Monday, November 3, 2025
Laura Bukavina: Presenting Real World Data on Adstiladrin at WSAUA25
Laura Bukavina: Presenting Real World Data on Adstiladrin at WSAUA25 / Adstiladrin, bladder cancer, cancer, Gabriela M. Díaz, Laura Bukavina, OncoDaily,
oncodaily.com
November 4, 2025 at 4:57 AM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Monday, November 3, 2025
Published on Monday, November 3, 2025
When you are undergoing an intravesical treatment such as Chemotherapy, BCG, Gemcitabine, Adstiladrin, etc. does you doctor make you roll from side-to-side to coat your bladder?
#bladdercancer #bladdercancerawareness #bladdercancerwarrior
#bladdercancer #bladdercancerawareness #bladdercancerwarrior
November 13, 2025 at 11:03 PM
When you are undergoing an intravesical treatment such as Chemotherapy, BCG, Gemcitabine, Adstiladrin, etc. does you doctor make you roll from side-to-side to coat your bladder?
#bladdercancer #bladdercancerawareness #bladdercancerwarrior
#bladdercancer #bladdercancerawareness #bladdercancerwarrior
The NCCN guidelines have now added nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A recommendation for patients with BCG-unresponsive NMIBC with papillary Ta/T1 tumors without concomitant carcinoma in situ. #BladderCancer #NMIBC #oncology
🔗 Read more: www.onclive.com/view/nadofar...
🔗 Read more: www.onclive.com/view/nadofar...
Nadofaragene Firadenovec Is Added to NCCN Guidelines in BCG-Unresponsive Papillary NMIBC Without CIS | OncLive
Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.
www.onclive.com
March 20, 2026 at 5:23 PM
The NCCN guidelines have now added nadofaragene firadenovec-vncg (Adstiladrin) as a category 2A recommendation for patients with BCG-unresponsive NMIBC with papillary Ta/T1 tumors without concomitant carcinoma in situ. #BladderCancer #NMIBC #oncology
🔗 Read more: www.onclive.com/view/nadofar...
🔗 Read more: www.onclive.com/view/nadofar...
Signal or noise? > adstiladrin bcg-unresponsive non-muscle-invasive bladder
cancer nmibc gene therapy - Pharmacy Practice News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
cancer nmibc gene therapy - Pharmacy Practice News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
adstiladrin bcg-unresponsive non-muscle-invasive bladder
cancer nmibc gene therapy - Pharmacy Practice News
adstiladrin bcg-unresponsive non-muscle-invasive bladder cancer nmibc gene therapy Pharmacy Practice News
dlvr.it
November 14, 2025 at 2:59 PM
Signal or noise? > adstiladrin bcg-unresponsive non-muscle-invasive bladder
cancer nmibc gene therapy - Pharmacy Practice News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
cancer nmibc gene therapy - Pharmacy Practice News >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
Signal or noise? > Ferring Highlights New Real-World Research with ADSTILADRIN®
(nadofaragene firadenovec-vncg) in Clinical Practice -
BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharma #pharmaceutical
(nadofaragene firadenovec-vncg) in Clinical Practice -
BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharma #pharmaceutical
Ferring Highlights New Real-World Research with ADSTILADRIN®
(nadofaragene firadenovec-vncg) in Clinical Practice -
BioSpace
Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice BioSpace
dlvr.it
October 29, 2025 at 6:00 AM
Signal or noise? > Ferring Highlights New Real-World Research with ADSTILADRIN®
(nadofaragene firadenovec-vncg) in Clinical Practice -
BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharma #pharmaceutical
(nadofaragene firadenovec-vncg) in Clinical Practice -
BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharma #pharmaceutical
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR
FDA clears the first cell-based gene therapy for recessive-dystrophic EB and a new plant to scale ADSTILADRIN bladder-cancer production. CAR-T30 hits 100 % r...
dlvr.it
May 4, 2025 at 11:37 AM
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR
FDA clears the first cell-based gene therapy for recessive-dystrophic EB and a new plant to scale ADSTILADRIN bladder-cancer production. CAR-T30 hits 100 % r...
dlvr.it
May 4, 2025 at 11:37 AM
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR
FDA clears the first cell-based gene therapy for recessive-dystrophic EB and a new plant to scale ADSTILADRIN bladder-cancer production. CAR-T30 hits 100 % r...
dlvr.it
May 2, 2025 at 1:54 PM
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR
LucidQuest
109 subscribers
<__slot-el _="@=2388,x=188,y=584,w=94,h=36,co=15;15;15;1.0">
<__slot-el _="@=2404,x=188,y=620,w=0,h=0,co=15;15;15;1.0">
FDA clears the first cell-based gene therapy for recessive-dystrophic EB and a new plant to scale ADSTILADRIN bladder-cancer production. CAR-T30 hits 100 % responses in refractory lymphoma, Penn’s “armored” CAR T breaches solid tumors, and off-the-shelf NK-CARs erase blood cancers. Europe approves Vyjuvek, while India launches its inaugural hemophi
...more
dlvr.it
May 1, 2025 at 3:04 PM
LucidQuest YouTube > CGT News by LucidQuest: EB Breakthrough, Solid-Tumor CAR T, AI-CRISPR Subscribe for more!
Thoughts on this? >> Ferring Unveils New Data with ADSTILADRIN® (nadofaragene
firadenovec-vncg) at 112th Annual Meeting of the Japanese
Urological Association - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
firadenovec-vncg) at 112th Annual Meeting of the Japanese
Urological Association - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene
firadenovec-vncg) at 112th Annual Meeting of the Japanese
Urological Association - BioSpace
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association BioSpace
dlvr.it
April 22, 2025 at 5:30 AM
Thoughts on this? >> Ferring Unveils New Data with ADSTILADRIN® (nadofaragene
firadenovec-vncg) at 112th Annual Meeting of the Japanese
Urological Association - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
firadenovec-vncg) at 112th Annual Meeting of the Japanese
Urological Association - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #competitivemarketing #pharma
Thoughts on this? >> First Real-World Outcomes Data for ADSTILADRIN®
(nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO
Genitourinary Cancers Symposium -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical
(nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO
Genitourinary Cancers Symposium -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical
First Real-World Outcomes Data for ADSTILADRIN®
(nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO
Genitourinary Cancers Symposium - BioSpace
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium BioSpace
dlvr.it
February 13, 2025 at 9:31 AM
Thoughts on this? >> First Real-World Outcomes Data for ADSTILADRIN®
(nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO
Genitourinary Cancers Symposium -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical
(nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO
Genitourinary Cancers Symposium -… >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #biotech #pharmaceutical
🚨New in #Oncology!
🔹 Ferring showcases new real-world evidence for ADSTILADRIN® (nadofaragene firadenovec-vncg) in clinical practice.
🔹 3 abstracts to be presented at the 101st Annual Meeting of the Western Section AUA, including data from the ABLE-41 real-world study on bladder cancer patients.
🔹 Ferring showcases new real-world evidence for ADSTILADRIN® (nadofaragene firadenovec-vncg) in clinical practice.
🔹 3 abstracts to be presented at the 101st Annual Meeting of the Western Section AUA, including data from the ABLE-41 real-world study on bladder cancer patients.
October 29, 2025 at 1:30 PM
🚨New in #Oncology!
🔹 Ferring showcases new real-world evidence for ADSTILADRIN® (nadofaragene firadenovec-vncg) in clinical practice.
🔹 3 abstracts to be presented at the 101st Annual Meeting of the Western Section AUA, including data from the ABLE-41 real-world study on bladder cancer patients.
🔹 Ferring showcases new real-world evidence for ADSTILADRIN® (nadofaragene firadenovec-vncg) in clinical practice.
🔹 3 abstracts to be presented at the 101st Annual Meeting of the Western Section AUA, including data from the ABLE-41 real-world study on bladder cancer patients.